In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total transaction value of up to $2.4 billion. The deal centers on Orna’s proprietary circular RNA (oRNA)
The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP National Employment Report "NER Pulse" data, released throughout the month, has revealed four consecutive weeks
Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.
The global pharmaceutical landscape underwent a seismic shift today, February 24, 2026, as the two pioneers of the weight loss drug revolution reported vastly different outlooks for the coming year. While Eli Lilly and Co. (LLY:NYSE) raised its 2026 revenue guidance to record-breaking levels, its primary rival, Novo Nordisk
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4 2025 earnings beat, showcasing the immense scaling power of its telehealth platform. On the other, the company is embroiled in [...]
Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.
Animal health company Elanco (NYSE:ELAN) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 12.2% year on year to $1.14 billion. Guidance for next quarter’s revenue was better than expected at $1.29 billion at the midpoint, 1% above analysts’ estimates. Its non-GAAP profit of $0.13 per share was 15.6% above analysts’ consensus estimates.
Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.8% in the afternoon session after a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial.
